中国当代儿科杂志2012，Vol.14Issue(3)：236-240,5.
儿童肺动脉高压的药物治疗进展
Progress in pharmacotherapy of pulmonary arterial hypertension in children
虞燕萍1
作者信息
- 1. 杭州市第一人民医院儿科,浙江杭州310006
- 折叠
摘要
Abstract
This paper provides an overview of the current state of pharmacotherapy in children with pulmonary arterial hypertension (PAH) and a brief introduction to the potentially novel pharmacologic targets for PAH. Currently, 3 classes of drugs including prostacyclin analogues, endothelin receptor antagonists and phosphodiesterase-5 inhibitors are approved for the treatment of PAH in children, which has led to improved hemodynamics, increased exercise capacity and prolonged survival. Despite these improvements, there is still a need to carry out well-designed, randomized, controlled studies with larger samples. In addition, novel drugs targeting other molecular pathways should be developed.关键词
肺动脉高压/药物治疗/儿童Key words
Pulmonary arterial hypertension/ Pharmacotherapy/ Child分类
医药卫生引用本文复制引用
虞燕萍..儿童肺动脉高压的药物治疗进展[J].中国当代儿科杂志,2012,14(3):236-240,5.
